EffRx Pharmaceuticals SA

Binosto

Binosto® – The First and Only Buffered Solution for the Treatment of Osteoporosis

Pharmaceutical Form:

Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution that represents a true breakthrough in the treatment of osteoporosis – especially for those patients who prefer not to swallow tablets, or have difficulties swallowing pills. Taken just once a week, with a reduced volume of water to drink and no risk of a tablet getting lodged in the esophagus, Binosto® has the potential to improve long-term patient compliance and adherence to therapy, thereby decreasing the risk of disabling fractures.

Indication:

Europe: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.

United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.